IN2013MU02905A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02905A
IN2013MU02905A IN2905MU2013A IN2013MU02905A IN 2013MU02905 A IN2013MU02905 A IN 2013MU02905A IN 2905MU2013 A IN2905MU2013 A IN 2905MU2013A IN 2013MU02905 A IN2013MU02905 A IN 2013MU02905A
Authority
IN
India
Prior art keywords
preparation
improved process
relates
ethoxy
phenyl
Prior art date
Application number
Other languages
English (en)
Inventor
Shri Prakash Dhar Dwivedi
Ramesh Chandra Singh
Jagdish Maganlal Patel
Vikas Patel
Vishwadeepak Rama Pati Tripathi
Pranav Jitendra Gangwar
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to US14/916,402 priority Critical patent/US10112898B2/en
Priority to PCT/IN2014/000584 priority patent/WO2015033357A2/en
Priority to IN2905MU2013 priority patent/IN2013MU02905A/en
Publication of IN2013MU02905A publication Critical patent/IN2013MU02905A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333Radicals substituted by oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2905MU2013 2013-09-06 2014-09-05 IN2013MU02905A (cg-RX-API-DMAC7.html)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/916,402 US10112898B2 (en) 2013-09-06 2014-09-05 Process for the preparation of saroglitazar pharmaceutical salts
PCT/IN2014/000584 WO2015033357A2 (en) 2013-09-06 2014-09-05 An improved process for the preparation of pyrrole derivatives
IN2905MU2013 IN2013MU02905A (cg-RX-API-DMAC7.html) 2013-09-06 2014-09-05

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2905MU2013 IN2013MU02905A (cg-RX-API-DMAC7.html) 2013-09-06 2014-09-05

Publications (1)

Publication Number Publication Date
IN2013MU02905A true IN2013MU02905A (cg-RX-API-DMAC7.html) 2015-07-03

Family

ID=52023583

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2905MU2013 IN2013MU02905A (cg-RX-API-DMAC7.html) 2013-09-06 2014-09-05

Country Status (3)

Country Link
US (1) US10112898B2 (cg-RX-API-DMAC7.html)
IN (1) IN2013MU02905A (cg-RX-API-DMAC7.html)
WO (1) WO2015033357A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569248T3 (es) 2011-01-31 2016-05-09 Cadila Healthcare Limited Tratamiento para la lipodistrofia
JP6246895B2 (ja) 2013-04-22 2017-12-13 カディラ・ヘルスケア・リミテッド 非アルコール性脂肪性肝疾患(nafld)のための新規組成物
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (cg-RX-API-DMAC7.html) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (cg-RX-API-DMAC7.html) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US12016849B2 (en) * 2016-10-12 2024-06-25 Bonafide Health, Llc Magnesium picolinate compositions and methods of use
JP6840853B2 (ja) 2016-12-09 2021-03-10 カディラ・ヘルスケア・リミテッド 原発性胆汁性胆管炎の治療
US20220169603A1 (en) * 2019-03-11 2022-06-02 Cadila Healthcare Ltd. Novel salts, crystalline forms and premix of hypolipidemic agent
US12201611B2 (en) * 2020-07-24 2025-01-21 Zydus Lifesciences Limited Composition comprising high purity pyrrole derivative and method for preparation thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR950702545A (ko) 1992-07-03 1995-07-29 데이빗 로버츠 약제로서의 헤테로시클릭 화합물(Heterocyclic compounds as pharmaceutical)
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
CN1094940C (zh) 1995-04-28 2002-11-27 第一制药株式会社 具有抗肿瘤活性的紫杉酚衍生物
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6130214A (en) 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
JP2002527520A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用
JP2002527516A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
SK287294B6 (sk) 2000-01-19 2010-05-07 Cadila Healthcare Ltd. Pyrolové zlúčeniny, spôsoby prípravy, farmaceutická kompozícia, použitie a medziprodukty
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
US6514995B1 (en) 2000-09-25 2003-02-04 Advanced Research And Technology Institute, Inc. Enediyne compounds and methods related thereto
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20070051626A1 (en) 2003-09-26 2007-03-08 Chiho Itou Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
CN102140090A (zh) 2004-03-15 2011-08-03 武田药品工业株式会社 二肽基肽酶抑制剂
US20090196923A1 (en) 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
EP2641596B1 (en) 2009-11-26 2018-05-02 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
RU2013121270A (ru) 2010-10-12 2014-11-20 Серекор Инк. Композиции против кашля, содержащие мемантин
ES2569248T3 (es) * 2011-01-31 2016-05-09 Cadila Healthcare Limited Tratamiento para la lipodistrofia
JP6246895B2 (ja) 2013-04-22 2017-12-13 カディラ・ヘルスケア・リミテッド 非アルコール性脂肪性肝疾患(nafld)のための新規組成物
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (cg-RX-API-DMAC7.html) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015029066A1 (en) 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (cg-RX-API-DMAC7.html) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
US20160194280A1 (en) 2016-07-07
WO2015033357A2 (en) 2015-03-12
WO2015033357A3 (en) 2015-05-07
US10112898B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
IN2013MU02905A (cg-RX-API-DMAC7.html)
PH12020551628A1 (en) A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
MY181898A (en) Heterocyclic compounds and uses thereof
MY150542A (en) Cmet inhibitors
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
TN2011000673A1 (en) Bace inhibitors
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
MX353578B (es) Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
EA200900441A1 (ru) Способы и интермедиаты для получения ингибиторов интегразы
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
HUE041725T2 (hu) (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
CL2011003009A1 (es) Proceso de preparacion de compuestos derivados de 4-fenil-3,5-(tio)piranodionas; compuesto intermediario; y preparacion de dicho intermediario.
CL2013000797A1 (es) Proceso de preparacion de (2r,3r)-3-{4-(s-(ciclo)alquil-sulfonimidoil)fenil}amino}-5-(trifluorometil)pirimidin-4-il}oxi}butan-2-2ol inhibidores; y los compuestos intermediarios considerados.
MX2015017156A (es) Inhibidores de bace.
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
IN2013MU03862A (cg-RX-API-DMAC7.html)
MX2011006560A (es) Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple.
WO2013175499A3 (en) Process for the preparation of 5-(4-[4-(5-cyano-1 h-indol-3-yl)butyl]piperazin-1 -yl)benzofuran-2-carboxamide and intermediates thereof, polymorphic forms thereof
IN2013MU00665A (cg-RX-API-DMAC7.html)
PH12018502246A1 (en) Substituted fused pyrimidinone compounds